Grading local side effects of sublingual immunotherapy for respiratory allergy: Speaking the same language

Journal of Allergy and Clinical Immunology

Volumn 132, Issue 1, 2013, Pages 93-98

  Passalacqua, Giovanni ^a   Baena Cagnani, Carlos E ^b   Bousquet, Jean ^c   Canonica, Giorgio Walter ^a   Casale, Thomas B ^d   Cox, Linda ^e   Durham, Stephen R ^f   Larenas Linnemann, Desiréé ^g   Ledford, Dennis ^h   Pawankar, Ruby ⁱ   Potter, Paul ^j   Rosario, Nelson ^k   Wallace, Dana ^l   Lockey, Richard F ^h  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSIDAD CATÓLICA DE CÓRDOBA   (Argentina)

^c HÔPITAL ARNAUD DE VILLENEUVE   (France)

^d CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NOVA SOUTHEASTERN UNIVERSITY   (United States)

^f NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^g Hospital Medica Sur   (Mexico)

^h UNIVERSITY OF SOUTH FLORIDA   (United States)

ⁱ NIPPON MEDICAL SCHOOL   (Japan)

^j UNIVERSITY OF CAPE TOWN   (South Africa)

^k FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^l Asthma and Immunology   (United States)

more..

Author keywords

Grading; Local side effects; Safety; Sublingual immunotherapy

Indexed keywords

ALLERGEN; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; GRASS POLLEN EXTRACT; PLACEBO; SPASMOLYTIC AGENT;

ABDOMINAL PAIN; ARTICLE; ASTHMA; DIARRHEA; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG NOMENCLATURE; DRUG SAFETY; DYSGEUSIA; EAR PRURITUS; FOLLOW UP; FORCED EXPIRATORY VOLUME; GLOSSODYNIA; HEARTBURN; HUMAN; MEDICAL DICTIONARY FOR REGULATORY ACTIVITIES; MOUTH ULCER; NAUSEA; ORAL PRURITUS; PHARYNX EDEMA; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT ALLERGY; RHINOCONJUNCTIVITIS; SELF CONCEPT; STOMACH PAIN; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; SWELLING; THROAT IRRITATION; TONGUE SWELLING; TONGUE ULCER; URTICARIA; UVULAR EDEMA; VOMITING;

EID: 84882830218     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2013.03.039     Document Type: Article

References (59)

1. Scadding G, Brostoff J. Low dose sublingual therapy in patients with allergic rhinitis due to dust mite. Clin Allergy 1986;16:483-91.
2. Windom HH, Lockey RF. An update on the safety of specific immunotherapy. Curr Opin Allergy Clin Immunol 2008;8:571-6.
3. Bousquet RF, Lockey RF, Malling RF, editors. World Health Organization position paper. Allergen immunotherapy: therapeutical vaccines for allergic diseases. Allergy 1998;53(suppl):1-42.
4. Bousquet RF, Van Cauwenberge RF, editors. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108(5 suppl):S146-50.
5. American Medical Association. Current procedural terminology (CPT) 2005 standard edition. Chicago: American Medical Association; 2005.
6. Wilson DR, Torres L, Durham SR. Sublingual immunotherapy for allergic rhinitis. Allergy 2005;60:3-8.
7. Calamita Z, Saconato H, Pela AB, Atallah AN. Efficacy of sublingual immunotherapy in asthma. Systematic review of randomized clinical trials. Allergy 2006;61:1162-72.
8. Penagos M, Passalacqua G, Compalati E, Baena-Cagnani CE, Orozco S, Pedroza A, et al. Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest 2008;133:599-609.
9. Penagos M, Compalati E, Tarantini F, Baena-Cagnani R, Huerta J, Passalacqua G, et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol 2006;97:141-8.
10. Compalati E, Passalacqua G, Bonini M, Canonica GW. The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis. Allergy 2009;64:1570-9.
11. Di Bona D, Plaia A, Scafidi V, Leto-Barone MS, Di Lorenzo G Efficacy of sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a systematic review and meta-analysis. J Allergy Clin Immunol 2010;126:558-66.
12. Radulovic S, Calderon MA, Duncan W, Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev 2010;(8):CD002893.
13. Calderon MA, Penagos M, Sheikh A, Canonica GW, Durham S. Sublingual immunotherapy for treating allergic conjunctivitis. Cochrane Database Syst Rev 2011;(6):CD007685.
14. Canonica GW, Bousquet J, Casale T, Lockey RF, Baena-Cagnani CE, Pawankar R, et al, editors. WAO position paper on sublingual immunotherapy. Allergy 2009;64(suppl 91):1-15.
15. Cox L, Larenas-Linneman D, Nolte H, Weldon D, Finegold I, Nelson HS. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol 2006;117:1021-35.
16. Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G. Speaking the same language: the World Allergy Organization subcutaneous immunotherapy systemic reaction grading system. J Allergy Clin Immunol 2010;125:569-74.
17. Medical Dictionary for Regulatory Activities (MedDRA). Maintenance support services and organization. Available at: http://www.meddramsso.com/. Accessed July 2012.
18. Andre C, Vatrinet C, Galvain S, Carat F, Sicard H. Safety of sublingual swallow immunotherapy in children and adults. Int Arch Allergy Immunol 2000;121:229-34.
19. Gidaro GB, Frati F, Sensi L, Marcucci F, Incorvaia C, Ciprandi G The safety of sublingual-swallow immunotherapy: an analysis of published studies. Clin Exp Allergy 2005;35:565-71.
20. Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S. Sublingual immunotherapy with once-daily grass-allergen tablets: a randomised controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;117:802-9.
21. Dahl R, Kapp A, Colombo G, de Monchy JG, Rak S, Emminger W, et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;118:434-40.
22. Didier A, Malling HJ, Worm M, Horak F, Jager S, Montagut A, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007;120:1338-45.
23. Wahn U, Tabar A, Kuna P, Halken S, Montagut A, de Beaumont O, et al. Efficacy and safety of 5 grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol 2009;123:160-6.
24. Ott H, Sieber J, Brehler R, Folster-Holst R, Kapp A, Klimek L, et al. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study. Allergy 2009;64:179-86.
25. Bufe A, Eberle P, Franke-Beckmann E, Funck J, Kimmig M, Klimek L, et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol 2009;123:167-73.
26. Blaiss M, Maloney J, Nolte H, Gawchik S, Yao R, Skoner DP. Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. J Allergy Clin Immunol 2011;127:64-71.
27. Nelson HS, Nolte H, Creticos P, Maloney J, Wu J, Bernstein DI. Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. J Allergy Clin Immunol 2011;127:72-80.
28. Didier A, Worm M, Horak F, Sussman G, de Beaumont O, Le Gall M, et al. Sustained 3-year efficacy of pre-and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis. J Allergy Clin Immunol 2011;128:559-66.
29. Durham SR, Emminger W, Kapp A, de Monchy JG, Rak S, Scadding GK. SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol 2012;129:717-25.
30. Halken S, Agertoft L, Seidenberg J, Bauer CP, Payot F, Martin-Munoz MF, et al. Five-grass pollen 300IR SLIT tablets: efficacy and safety in children and adolescents. Pediatr Allergy Immunol 2010;21:970-6.
31. Di Rienzo V, Pagani A, Parmiani S, Passalacqua G, Canonica GW. Post-marketing surveillance study on the safety of sublingual immunotherapy in children. Allergy 1999;54:1110-3.
32. Lombardi C, Gargioni S, Melchiorre A, Passalacqua G. Safety of sublingual immunotherapy in adults: a post marketing surveillance study. Allergy 2001; 56:889-92.
33. Pajno GB, Peroni DG, Vita D, Pietrobelli A, Parmiani S, Boner AL. Safety of Sublingual immunotherapy in children with asthma. Paediatr Drugs 2003;5: 777-81.
34. Fiocchi A, Pajno G, La Grutta S, Pezzuto F, Incorvaia C, Sensi L, et al. Safety of SLIT in children aged 3 to 7 years. Ann Allergy Asthma Immunol 2005;95:254-8.
35. Drachenberg KJ, Urban E, Proll S, Woroniecki SR. Sublingual specific immunotherapy for adults and children: a post marketing survey. Allergol Immunopathol 2004;32:76-81.
36. Agostinis F, Tellarini L, Falagiani P, Canonica GW, Passalacqua G. Safety of SLIT in very young children. Allergy 2005;60:133.
37. Di Rienzo V, Minelli M, Musarra A, Sambugaro R, Pecora S, Canonica WG, et al. Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years. Clin Exp Allergy 2005;35:560-4.
38. Rodriguez-Perez N, Ambriz-Moreno Mde J, Canonica GW, Penagos M. Frequency of acute systemic reactions in patients with allergic rhinitis and asthma treated with sublingual immunotherapy. Ann Allergy Asthma Immunol 2008; 101:304-10.
39. Agostinis F, Foglia C, Landi M, Cottini M, Lombardi C, Canonica GW, et al. The safety of sublingual immunotherapy with one or multiple pollen allergens in children. Allergy 2008;63:1637-9.
40. Lombardi C, Gargioni S, Cottini M, Canonica GW, Passalacqua G. The safety of sublingual immunotherapy with one or more allergens in adults. Allergy 2008;63:375-6.
41. Antico A, Pagani M, Crema A. Anaphylaxis by latex sublingual immunotherapy. Allergy 2006;61:1236-7.
42. Eifan AO, Keles S, Bahceciler NN, Barlan IB. Anaphylaxis to multiple pollen allergen sublingual immunotherapy. Allergy 2007;62:567-8.
43. De Groot H, Bijl A. Anaphylactic reaction after the first dose of sublingual immunotherapy with grass pollen tablet. Allergy 2009;64:963-4.
44. Blazowski L. Anaphylactic shock because of sublingual immunotherapy overdose during third year of maintenance dose. Allergy 2008;63:374.
45. Dunsky E, Goldstein MF, Dvorin MJ, Belecanech G. Anaphylaxis due to sublingual immunotherapy. Allergy 2006;61:1235.
46. Simons FER, Ardusso L, Bilo B, El Gamal Y, Ledford DK, Ring J, et al. Anaphylaxis guidelines: summary. J Allergy Clin Immunol 2011;127:587-93.
47. Cochard MM, Eigenmann PA. Sublingual immunotherapy is not always a safe alternative to subcutaneous immunotherapy. J Allergy Clin Immunol 2009;124: 378-9.
48. Coop CA, Tankersley MS. Patient perceptions regarding local reactions from allergen immunotherapy injections. Ann Allergy Asthma Immunol 2008;101:96-100.
49. Position paper: immunotherapy. (EAACI) The European Academy of Allergology and Clinical Immunology. Allergy 1993;48:7-35.
50. Kleine-Tebbe J, Ribel M, Herold DA. Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial. Allergy 2006;61:181-4.
51. Larsen H, Poulsen LK, Melac M, Combebias A, Andre C, Malling HJ. Safety and tolerability of grass pollen tablets in sublingual immunotherapy-a phase-1 study. Allergy 2006;61:1173-6.
52. Ibanez MD, Kaiser F, Knecht R, Armentia A, Schopfer H, Tholstrup B, et al. Safety of specific sublingual immunotherapy with SQ standardized grass allergen tablets in children. Pediatr Allergy Immunol 2007;18:516-22.
53. Rodriguez F, Boquete M, Ibanez MD, de la Torre-Martinez F, Tabar AI. Once daily sublingual immunotherapy without updosing-a new treatment schedule. Int Arch Allergy Immunol 2006;140:321-6.
54. Sabin BR, Saltoun CA, Avila PC. Advances in upper airway diseases and allergen immunotherapy. J Allergy Clin Immunol 2011;127:342-50.
55. Peden DB, Bush RK. Advances in environmental and occupational respiratory disease in 2010. J Allergy Clin Immunol 2011;127:696-700.
56. Nelson HS. Subcutaneous immunotherapy. J Allergy Clin Immunol 2011;128:907.
57. Casale TB, Stokes Jr. Future forms of immunotherapy. J Allergy Clin Immunol 2011;127:8-15.
58. Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf 1999;20:109-17.
59. Bousquet C, Lagier G, Lillo-Le Louet A, Le Beller C, Venot A, Jaulent MC. Appraisal of the MedDRA conceptual structure for describing and grouping adverse drug reactions. Drug Saf 2005;28:19-34.